Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-Up of Subjects Treated With NTLA-2002
2023-507956-56-00Phase 2Authorised
- Sponsor
- Intellia Therapeutics
- Start
- Nov 2023
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of lonvoguran in hereditary angioedema (HAE), sponsored by Intellia Therapeutics. Primary endpoints: Incidence of treatment-related adverse events, Incidence of treatment-related serious adverse events and 1 more. Planned start Nov 2023; status: authorised.
02
Drugs
lonvoguran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2023-507956-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507956-56-00.